AIDS Treatment News, the world's first treatment newsletter for people with HIV, reports on mainstream and alternative treatment, access to care, Web resources, public policy, and political action.
KP-1461, an experimental HIV drug already in a phase II trial, works so differently from other antiretrovirals that at first glance it looked like science fiction, and we found it hard to take seriously as a current possibility today. In fact this drug is highly credible, and based on elegant science that goes back at least 25 years. KP-1461 is the only antiretroviral in human use or testing that can eradicate HIV from laboratory cell cultures. No one knows how it will work in people -- but we might know by the second quarter of 2008, when the current phase II trial could be complete. AIDS Treatment News interviewed Dr. Stephen Becker, a leading AIDS physician and researcher who is vice president of clinical development at
Koronis Pharmaceuticals, in Seattle, Washington.
The Fair Pricing Coalition and others are collecting signatures until this important Merck drug (the first integrase inhibitor) is approved and launched.
Our new toll-free editorial and business number is 1-800-804-8845 -- weekdays 2 p.m. to 5 p.m. Eastern time (11 a.m. to 2 p.m. Pacific time), or leave a message. This number is for editorial and business calls; please do not list it as a hotline.
See our selection of treatment news updated every day at www.aidsnews.org/now -- free, ad-free, and registration-free. You can scan AIDS treatment developments in a few minutes a week, right on the Web page -- or subscribe by email or RSS if you wish. For the latest background on this project, see www.aidsnews.org/doc.
Fundraising isn't working well today and needs new business models. This writer developed a series of designs from a new approach to ecommerce: online financial accounts that can reproduce at their owner's command, creating new accounts that can inherit any number of capabilities, and evolve in grassroots community use (the idea is confusing at first because it is so new -- we will explain). From this basic idea come potential fundraising innovations that you never heard of before. In this series of four short articles we put some of them on the table for public discussion and use. All our work is rights-free.
Why is fundraising so hard when millions of people want to help, and have plenty of surplus money between them -- thousands of times what AIDS and health activism would need? How could we provide better opportunities for giving?
Fundraising campaigns could be elaborate local or global contests or games to raise money for good causes -- showing financial results instantly, costing almost nothing, and letting donors, teams and individual fundraisers make their mark.
Suppose a major donor anywhere in the world could sponsor tens of thousands (or any number) of copies of a song, video, or any other digital "content" -- letting tens of thousands of people in social networks just click to download free, with no registration ever, instantly paying the artists or a cause by the act of free downloading itself. And each sponsor can deliver a message to the thousands of anonymous end users who download from his or her contribution. We show how independent artists could market globally at no expense if people care about their work -- offering an alternative to corporate monoculture. Or artists could donate their digital original to an organization that will use it this way to raise
funds.
A Philadelphia program for people with a mental health diagnosis who are HIV-positive has won national recognition. We interviewed its founder for ideas and approaches others can use.
During the first two weeks after release, prisoners in Washington State had 129 times the death rate from drug overdose, compared to other state residents -- probably because they did not know how much less drug they could tolerate, after taking little or none of it prison. Cardiovascular disease, homicide, suicide, cancer, and traffic accidents also caused excessive deaths.
The inventor of the machine used to count T-cells, collect stem cells, and measure or collect many other rare cells was awarded the prestigious Kyoto Prize for advanced technology, at a ceremony in Japan.
The Kaiser Family Foundation and mtvU announced a contest for the best concept for a Web-based video game "to help raise awareness about HIV/AIDS among 15-24 year olds in the U.S. and to promote personal action in response to the epidemic."